Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Fuentes Antras J ^a   Ioan, A M ^a   Tunon J ^a   Egido, J ^a,b   Lorenzo, O ^a,b  

^a 28400 Madrid   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; APOPTOSIS ASSOCIATED SPECK LIKE PROTEIN CONTAINING AN N TERMINAL CASPASE RECRUITMENT DOMAIN CARD; CASPASE; CHAPERONIN 60; CRYOPYRIN; ENDOTOXIN; HEAT SHOCK PROTEIN 70; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROCASPASE 1; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; SIRTUIN 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

CARDIOVASCULAR INFLAMMATION; CELL ACTIVATION; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DRUG TARGETING; HUMAN; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 84897536939     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/847827     Document Type: Review

References (124)

1. Boudina S., Abel E. D., Diabetic cardiomyopathy revisited. Circulation 2007 115 25 3213 3223 2-s2.0-34347352169 10.1161/CIRCULATIONAHA.106.679597 (Pubitemid 47012236)
2. Rubler S., Dlugash J., Yuceoglu Y. Z., Kumral T., Branwood A. W., Grishman A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. The American Journal of Cardiology 1972 30 6 595 602 2-s2.0-0015498586
3. Zhi Y. F., Prins J. B., Marwick T. H., Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews 2004 25 4 543 567 2-s2.0-4143140134 10.1210/er.2003-0012 (Pubitemid 39096070)
4. Palomer X., Salvado L., Barroso E., An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. International Journal of Cardiology 2013 168 4 3160 3172
5. Taegtmeyer H., McNulty P., Young M. E., Adaptation and maladaptation of the heart in diabetes-part I: general concepts. Circulation 2002 105 14 1727 1733 2-s2.0-0037046203 10.1161/01.CIR.0000012466.50373.E8 (Pubitemid 34298619)
6. Shiojima I., Komuro I., Molecular mechanisms of congestive heart failure. Nippon Rinsho 2006 64 5 826 831 2-s2.0-33745011863
7. Kannel W. B., Hjortland M., Castelli W. P., Role of diabetes in congestive heart failure: The Framingham Study. American Journal of Cardiology 1974 34 1 29 34 2-s2.0-0016251063
8. Westermann D., Rutschow S., Jäger S., Linderer A., Anker S., Riad A., Unger T., Schultheiss H.-P., Pauschinger M., Tschöpe C., Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007 56 3 641 646 2-s2.0-33847342561 10.2337/db06-1163 (Pubitemid 46348458)
9. Ramírez E., Klett-Mingo M., Ares-Carrasco S., Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes. Cardiovascular Diabetology 2013 12 1, article 172
10. Hamblin M., Friedman D. B., Hill S., Caprioli R. M., Smith H. M., Hill M. F., Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. Journal of Molecular and Cellular Cardiology 2007 42 4 884 895 2-s2.0-34047111193 10.1016/j.yjmcc.2006.12.018 (Pubitemid 46527591)
11. Pashkow F. J., Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? International Journal of Inflammation 2011 2011 514623
12. Mann D. L., Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circulation Research 2002 91 11 988 998 2-s2.0-0037195727 10.1161/01.RES.0000043825.01705.1B (Pubitemid 35416635)
13. Huang W., Glass C. K., Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 8 1542 1549 2-s2.0-77955170550 10.1161/ATVBAHA.109.191189
14. Yu X.-Y., Chen H.-M., Liang J.-L., Lin Q.-X., Tan H.-H., Fu Y.-H., Liu X.-Y., Shan Z.-X., Li X.-H., Yang H.-Z., Yang M., Li Y., Lin S.-G., Hyperglycemic myocardial damage is mediated by proinflammatory cytokine: macrophage migration inhibitory factor. PLoS ONE 2011 6 1 2-s2.0-79551541593 10.1371/journal.pone.0016239 e16239
15. Ares-Carrasco S., Picatoste B., Benito-Martín A., Zubiri I., Sanz A. B., Sánchez-Niño M. D., Ortiz A., Egido J., Tuñón J., Lorenzo O., Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. American Journal of Physiology-Heart and Circulatory Physiology 2009 297 6 H2109 H2119 2-s2.0-72249102361 10.1152/ajpheart.00157.2009
16. Haugen E., Chen J., Wikström J., Grönros J., Gan L. M., Fu L. X. M., Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats. International Journal of Cardiology 2007 115 1 24 28 2-s2.0-33845216828 10.1016/j.ijcard.2006.01.031 (Pubitemid 44855186)
17. Hamid T., Guo S. Z., Kingery J. R., Xiang X., Dawn B., Prabhu S. D., Cardiomyocyte NF- B p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovascular Research 2011 89 1 129 138 2-s2.0-78650443223 10.1093/cvr/cvq274
18. Lorenzo O., Picatoste B., Ares-Carrasco S., Ramírez E., Egido J., Tuñón J., Potential role of nuclear factor b in diabetic cardiomyopathy. Mediators of Inflammation 2011 2011 9 2-s2.0-79959251277 10.1155/2011/652097 652097
19. Lorenzo O., Ramírez E., Picatoste B., Egido J., Tuñón J., Alteration of energy substrates and ROS production in diabetic cardiomyopathy. Mediators of Inflammation 2013 2013 11 461967 10.1155/2013/461967
20. Dong B., Qi D., Yang L., TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. American Journal of Physiology-Heart and Circulatory Physiology 2012 303 6 H732 H742
21. Mohammad M. K., Morran M., Slotterbeck B., Leaman D. W., Sun Y., von Grafenstein H., Hong S.-C., McInerney M. F., Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. International Immunology 2006 18 7 1101 1113 2-s2.0-33745251699 10.1093/intimm/dxl045 (Pubitemid 43923428)
22. Coll R. C., O'Neill L. A. J., New insights into the regulation of signalling by toll-like receptors and nod-like receptors. Journal of Innate Immunity 2010 2 5 406 421 2-s2.0-77956025260 10.1159/000315469
23. Tsan M.-F., Gao B., Endogenous ligands of Toll-like receptors. Journal of Leukocyte Biology 2004 76 3 514 519 2-s2.0-4344627821 10.1189/jlb.0304127 (Pubitemid 39129081)
24. Frantz S., Kelly R. A., Bourcier T., Role of TLR-2 in the activation of nuclear factor B by oxidative stress in cardiac myocytes. Journal of Biological Chemistry 2001 276 7 5197 5203 2-s2.0-0035895913 10.1074/jbc.M009160200
25. Kawai T., Akira S., TLR signaling. Cell Death and Differentiation 2006 13 5 816 825 2-s2.0-33645960706 10.1038/sj.cdd.4401850
26. Methe H., Kim J.-O., Kofler S., Weis M., Nabauer M., Koglin J., Expansion of circulating toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005 111 20 2654 2661 2-s2.0-19644390754 10.1161/CIRCULATIONAHA.104.498865 (Pubitemid 40740866)
27. Frantz S., Ertl G., Bauersachs J., Toll-like receptor signaling in the ischemic heart. Frontiers in Bioscience 2008 13 15 5772 5779 2-s2.0-52049106096 10.2741/3114
28. Dasu M. R., Devaraj S., Park S., Jialal I., Increased Toll-Like Receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care 2010 33 4 861 868 2-s2.0-77953060025 10.2337/dc09-1799
29. Reyna S. M., Ghosh S., Tantiwong P., Meka C. S. R. M., Eagan P., Jenkinson C. P., Cersosimo E., Defronzo R. A., Coletta D. K., Sriwijitkamol A., Musi N., Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008 57 10 2595 2602 2-s2.0-58149359307 10.2337/db08-0038
30. Ma Y., Zhang X., Bao H., Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One 2012 7 7, article e40763
31. Boyd J. H., Mathur S., Wang Y., Bateman R. M., Walley K. R., Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF- B dependent inflammatory response. Cardiovascular Research 2006 72 3 384 393 2-s2.0-33750515851 10.1016/j.cardiores.2006.09.011 (Pubitemid 44665856)
32. Takahashi T., Toll-like receptors and myocardial contractile dysfunction. Cardiovascular Research 2008 78 1 3 4 2-s2.0-41149174126 10.1093/cvr/cvn044 (Pubitemid 351430973)
33. Shi H., Kokoeva M. V., Inouye K., Tzameli I., Yin H., Flier J. S., TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 2006 116 11 3015 3025 2-s2.0-33750584214 10.1172/JCI28898 (Pubitemid 44684486)
34. Schaeffler A., Gross P., Buettner R., Bollheimer C., Buechler C., Neumeier M., Kopp A., Schoelmerich J., Falk W., Fatty acid-induced induction of Toll-like receptor-4/nuclear factor- B pathway in adipocytes links nutritional signalling with innate immunity. Immunology 2009 126 2 233 245 2-s2.0-58149310977 10.1111/j.1365-2567.2008.02892.x
35. Fessler M. B., Rudel L. L., Brown J. M., Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Current Opinion in Lipidology 2009 20 5 379 385 2-s2.0-73349117487 10.1097/MOL.0b013e32832fa5c4
36. Qiao Y., Wang P., Qi J., Zhang L., Gao C., TLR-induced NF- B activation regulates NLRP3 expression in murine macrophages. FEBS Letters 2012 586 7 1022 1026 2-s2.0-84859266009 10.1016/j.febslet.2012.02.045
37. Ko H. J., Zhang Z., Jung D. Y., Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 2009 58 11 2536 2546 2-s2.0-70350560556 10.2337/db08-1361
38. Dasu M. R., Ramirez S., Isseroff R. R., Toll-like receptors and diabetes: a therapeutic perspective. Clinical Science 2012 122 5 203 214 2-s2.0-84855481978 10.1042/CS20110357
39. Zhang Y., Peng T., Zhu H., Zheng X., Zhang X., Jiang N., Cheng X., Lai X., Shunnar A., Singh M., Riordan N., Bogin V., Tong N., Min W.-P., Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4. Journal of Translational Medicine 2010 8, article 133 2-s2.0-78650043221 10.1186/1479-5876-8-133
40. Kolek M. J., Carlquist J. F., Muhlestein J. B., Whiting B. M., Horne B. D., Bair T. L., Anderson J. L., Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. American Heart Journal 2004 148 6 1034 1040 2-s2.0-10644236977 10.1016/j.ahj.2004.05.049 (Pubitemid 39646980)
41. Riad A., Meyer zu Schwabedissen H., Weitmann K., Variants of Toll-like receptor 4 predict cardiac recovery in patients with dilated cardiomyopathy. The Journal of Biological Chemistry 2012 287 32 27236 27243
42. Dasu M. R., Devaraj S., Zhao L., Hwang D. H., Jialal I., High glucose induces toll-like receptor expression in human monocytes Mechanism of activation. Diabetes 2008 57 11 3090 3098 2-s2.0-58149333718 10.2337/db08-0564
43. Ururahy M. A. G., Loureiro M. B., Freire-Neto F. P., de Souza K. S. C., Zuhl I., Brandão-Neto J., Hirata R. D. C., Doi S. D. Q., Arrais R. F., Hirata M. H., Almeida M. D. G., de Rezende A. A., Increased TLR2 expression in patients with type 1 diabetes: evidenced risk of microalbuminuria. Pediatric Diabetes 2012 13 2 147 154 2-s2.0-84857503216 10.1111/j.1399-5448.2011.00794.x
44. Schroder K., Zhou R., Tschopp J., The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010 327 5963 296 300 2-s2.0-74549184092 10.1126/science.1184003
45. Vandanmagsar B., Youm Y.-H., Ravussin A., Galgani J. E., Stadler K., Mynatt R. L., Ravussin E., Stephens J. M., Dixit V. D., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nature Medicine 2011 17 2 179 189 2-s2.0-79751512463 10.1038/nm.2279
46. Hirao K., Yumoto H., Takahashi K., Mukai K., Nakanishi T., Matsuo T., Roles of TLR2, TLR4, NOD2, and NOD1 in pulp fibroblasts. Journal of Dental Research 2009 88 8 762 767 2-s2.0-70349326627 10.1177/0022034509341779
47. Kummer J. A., Broekhuizen R., Everett H., Agostini L., Kuijk L., Martinon F., Van Bruggen R., Tschopp J., Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. Journal of Histochemistry and Cytochemistry 2007 55 5 443 452 2-s2.0-34247574122 10.1369/jhc.6A7101.2006 (Pubitemid 46668626)
48. Bracey N. A., Beck P. L., Muruve D. A., The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Experimental Physiology 2013 462 472
49. Coggins M., Rosenzweig A., The fire within: cardiac inflammatory signaling in health and disease. Circulation Research 2012 110 1 116 125 2-s2.0-84855384344 10.1161/CIRCRESAHA.111.243196
50. Jin C., Flavell R. A., Innate sensors of pathogen and stress: linking inflammation to obesity. Journal of Allergy and Clinical Immunology 2013 132 2 287 294
51. Wen H., Ting J. P.-Y., O'Neill L. A. J., A role for the NLRP3 inflammasome in metabolic diseases-did Warburg miss inflammation? Nature Immunology 2012 13 4 352 357 2-s2.0-84858630049 10.1038/ni.2228
52. Choi A. M. K., Nakahira K., Dampening insulin signaling by an NLRP3 "meta-flammasome" Nature Immunology 2011 12 5 379 380 2-s2.0-79955006431 10.1038/ni.2028
53. Latz E., Xiao T. S., Stutz A., Activation and regulation of the inflammasomes. Nature Reviews Immunology 2013 13 6 397 411
54. Bauernfeind F. G., Horvath G., Stutz A., Alnemri E. S., MacDonald K., Speert D., Fernandes-Alnemri T., Wu J., Monks B. G., Fitzgerald K. A., Hornung V., Latz E., Cutting edge: NF- B activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. Journal of Immunology 2009 183 2 787 791 2-s2.0-70249138036 10.4049/jimmunol. 0901363
55. Juliana C., Fernandes-Alnemri T., Kang S., Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. The Journal of Biological Chemistry 2012 287 43 36617 36622
56. Shimada K., Crother T. R., Karlin J., Dagvadorj J., Chiba N., Chen S., Ramanujan V. K., Wolf A. J., Vergnes L., Ojcius D. M., Rentsendorj A., Vargas M., Guerrero C., Wang Y., Fitzgerald K. A., Underhill D. M., Town T., Arditi M., Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 2012 36 3 401 414 2-s2.0-84858782430 10.1016/j.immuni.2012.01.009
57. Zhou R., Tardivel A., Thorens B., Choi I., Tschopp J., Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nature Immunology 2010 11 2 136 140 2-s2.0-75649096002 10.1038/ni.1831
58. Bauernfeind F., Rieger A., Schildberg F. A., NLRP3 inflammasome activity is negatively controlled by miR-223. The Journal of Immunology 2012 189 8 4175 4181
59. Zuurbier C. J., Jong W. M., Eerbeek O., Deletion of the innate immune NLRP3 receptor abolishes cardiac ischemic preconditioning and is associated with decreased Il-6/STAT3 signaling. PLoS One 2012 7 7, article e40643
60. Hermansson C., Lundqvist A., Wasslavik C., Reduced expression of NLRP3 and MEFV in human ischemic heart tissue. Biochemical and Biophysical Research Communications 2013 430 1 425 428
61. Merkle S., Frantz S., Schön M. P., Bauersachs J., Buitrago M., Frost R. J. A., Schmitteckert E. M., Lohse M. J., Engelhardt S., A role for caspase-1 in heart failure. Circulation Research 2007 100 5 645 653 2-s2.0-33947714585 10.1161/01.RES.0000260203.55077.61 (Pubitemid 46594878)
62. Verma D., Lerm M., Julinder R. B., Eriksson P., Söderkvist P., Särndahl E., Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation relation to common inflammatory diseases? Arthritis and Rheumatism 2008 58 3 888 894 2-s2.0-40549084310 10.1002/art.23286 (Pubitemid 351364891)
63. Verma D., Särndahl E., Andersson H., Eriksson P., Fredrikson M., Jönsson J.-I., Lerm M., Söderkvist P., The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1 β and IL-18 production. PLoS ONE 2012 7 4, artile e34977 2-s2.0-84859877626 10.1371/journal.pone.0034977
64. Dehghan A., Dupuis J., Barbalic M., Meta-analysis of genome-wide association studies in > 80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011 123 7 731 738
65. Kawaguchi M., Takahashi M., Hata T., Kashima Y., Usui F., Morimoto H., Izawa A., Takahashi Y., Masumoto J., Koyama J., Hongo M., Noda T., Nakayama J., Sagara J., Taniguchi S., Ikeda U., Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation 2011 123 6 594 604 2-s2.0-79951679204 10.1161/CIRCULATIONAHA.110.982777
66. Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M. T.-H., Brickey W. J., Ting J. P.-Y., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nature Immunology 2011 12 5 408 415 2-s2.0-79955038882 10.1038/ni.2022
67. Grishman E. K., White P. C., Savani R. C., Toll-like receptors, the NLRP3 inflammasome, and interleukin-1beta in the development and progression of type 1 diabetes. Pediatric Research 2012 71 6 626 632
68. Wahli W., Michalik L., PPARs at the crossroads of lipid signaling and inflammation. Trends in Endocrinology & Metabolism 2012 23 7 351 363
69. Burkart E. M., Sambandam N., Han X., Gross R. W., Courtois M., Gierasch C. M., Shoghi K., Welch M. J., Kelly D. P., Nuclear receptors PPAR β / δ and PPAR α direct distinct metabolic regulatory programs in the mouse heart. Journal of Clinical Investigation 2007 117 12 3930 3939 2-s2.0-36849068108 10.1172/JCI32578 (Pubitemid 350224102)
70. Wright J. J., Kim J., Buchanan J., Boudina S., Sena S., Bakirtzi K., Ilkun O., Theobald H. A., Cooksey R. C., Kandror K. V., Abel E. D., Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. Cardiovascular Research 2009 82 2 351 360 2-s2.0-67449161754 10.1093/cvr/cvp017
71. Palomer X., Álvarez-Guardia D., Rodríguez-Calvo R., Coll T., Laguna J. C., Davidson M. M., Chan T. O., Feldman A. M., Vázquez-Carrera M., TNF- α reduces PGC-1 α expression through NF- B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovascular Research 2009 81 4 703 712 2-s2.0-60149110303 10.1093/cvr/cvn327
72. Karakikes I., Kim M., Hadri L., Sakata S., Sun Y., Zhang W., Chemaly E. R., Hajjar R. J., Lebeche D., Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a. PloS one 2009 4 7, article e6474 2-s2.0-79952205383
73. Quintela A. M., Jimenez R., Gomez-Guzman M., Activation of peroxisome proliferator-activated receptor-b/-d (PPARb/d) prevents endothelial dysfunction in type 1 diabetic rats. Free Radical Biology & Medicine 2012 53 730 741
74. Collino M., Benetti E., Rogazzo M., Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-delta agonism correlates with impaired NLRP3 inflammasome activation. Biochemical Pharmacology 2013 85 2 257 264
75. Dasu M. R., Park S., Devaraj S., Jialal I., Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009 150 8 3457 3464 2-s2.0-67651166868 10.1210/en.2008-1757
76. Li C. B., Li X. X., Chen Y. G., Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension. Journal of Cellular and Molecular Medicine 2009 13 11-12 4444 4452
77. Álvarez-Guardia D., Palomer X., Coll T., Serrano L., Rodríguez-Calvo R., Davidson M. M., Merlos M., El Kochairi I., Michalik L., Wahli W., Vázquez-Carrera M., PPAR β / δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. Biochimica et Biophysica Acta 2011 1811 2 59 67 2-s2.0-78650605981 10.1016/j.bbalip.2010.11.002
78. Genolet R., Wahli W., Michalik L., PPARs as drug targets to modulate inflammatory responses? Current Drug Targets 2004 3 4 361 375 2-s2.0-8844238364 10.2174/1568010042634578 (Pubitemid 39534773)
79. Buroker N. E., Barboza J., Huang J.-Y., The I B α gene is a peroxisome proliferator-activated receptor cardiac target gene. FEBS Journal 2009 276 12 3247 3255 2-s2.0-66249093473 10.1111/j.1742-4658.2009.07039.x
80. Shimamoto A., Chong A. J., Yada M., Shomura S., Takayama H., Fleisig A. J., Agnew M. L., Hampton C. R., Rothnie C. L., Spring D. J., Pohlman T. H., Shimpo H., Verrier E. D., Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006 114 1 I270 I274 2-s2.0-33747178729 10.1161/CIRCULATIONAHA.105.000901 (Pubitemid 44297162)
81. Rodríguez-Calvo R., Serrano L., Coll T., Moullan N., Sánchez R. M., Merlos M., Palomer X., Laguna J. C., Michalik L., Wahli W., Vázquez-Carrera M., Activation of peroxisome proliferator-activated receptor β / δ inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor- B activity via extracellular signal-related kinase 1/2. Diabetes 2008 57 8 2149 2157 2-s2.0-50949105881 10.2337/db08-0176
82. Holness M. J., Samsuddin S., Sugden M. C., The role of PPARs in modulating cardiac metabolism in diabetes. Pharmacological Research 2009 60 3 185 194 2-s2.0-67651121708 10.1016/j.phrs.2009.04.006
83. Zandbergen F., Plutzky J., PPAR α in atherosclerosis and inflammation. Biochimica et Biophysica Acta 2007 1771 8 972 982 2-s2.0-34547597709 10.1016/j.bbalip.2007.04.021 (Pubitemid 47198548)
84. Kempster S. L., Belteki G., Forhead A. J., Fowden A. L., Catalano R. D., Lam B. Y., McFarlane I., Charnock-Jones D. S., Smith G. C. S., Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. American Journal of Physiology-Gastrointestinal and Liver Physiology 2011 300 2 G253 G263 2-s2.0-79251558406 10.1152/ajpgi.00397.2010
85. Lee G. S., Subramanian N., Kim A. I., The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 2012 492 7427 123 127
86. Rossol M., Pierer M., Raulien N., Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. Nature Communications 2012 3 1329
87. Qu Y., Misaghi S., Izrael-Tomasevic A., Phosphorylation of NLRC4 is critical for inflammasome activation. Nature 2012 490 7421 539 542
88. Kotas M. E., Gorecki M. C., Gillum M. P., Sirtuin-1 is a nutrient-dependent modulator of inflammation. Adipocyte 2013 2 2 113 118
89. Tanno M., Kuno A., Horio Y., Emerging beneficial roles of sirtuins in heart failure. Basic Research in Cardiology 2012 107 4 273
90. Kauppinen A., Suuronen T., Ojala J., Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal 2013 25 10 1939 1948
91. Yoshizaki T., Schenk S., Imamura T., Babendure J. L., Sonoda N., Bae E. J., Oh D. Y., Lu M., Milne J. C., Westphal C., Bandyopadhyay G., Olefsky J. M., SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. American Journal of Physiology-Endocrinology and Metabolism 2010 298 3 E419 E428 2-s2.0-77349087078 10.1152/ajpendo.00417.2009
92. Pfluger P. T., Herranz D., Velasco-Miguel S., Serrano M., Tschöp M. H., Sirt1 protects against high-fat diet-induced metabolic damage. Proceedings of the National Academy of Sciences of the United States of America 2008 105 28 9793 9798 2-s2.0-47749128879 10.1073/pnas.0802917105 (Pubitemid 352031379)
93. Alcendor R. R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., Tian B., Wagner T., Vatner S. F., Sadoshima J., Sirt1 regulates aging and resistance to oxidative stress in the heart. Circulation Research 2007 100 10 1512 1521 2-s2.0-34249669270 10.1161/01.RES.0000267723.65696.4a (Pubitemid 46834764)
94. Planavila A., Iglesias R., Giralt M., Villarroya F., Sirt1 acts in association with PPAR α to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovascular Research 2011 90 2 276 284 2-s2.0-79955397959 10.1093/cvr/cvq376
95. Yeung F., Hoberg J. E., Ramsey C. S., Keller M. D., Jones D. R., Frye R. A., Mayo M. W., Modulation of NF- B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO Journal 2004 23 12 2369 2380 2-s2.0-3242719545 10.1038/sj.emboj.7600244 (Pubitemid 38954844)
96. Liu T. F., Yoza B. K., El Gazzar M., Vachharajani V. T., McCall C. E., NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. Journal of Biological Chemistry 2011 286 11 9856 9864 2-s2.0-79953230829 10.1074/jbc.M110.196790
97. Zhu H., Yang Y., Wang Y., Li J., Schiller P. W., Peng T., MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. Cardiovascular Research 2011 92 1 75 84 2-s2.0-80052908737 10.1093/cvr/cvr145
98. Arslan F., Smeets M. B., O'Neill L. A. J., Keogh B., McGuirk P., Timmers L., Tersteeg C., Hoefer I. E., Doevendans P. A., Pasterkamp G., De Kleijn D. P. V., Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody. Circulation 2010 121 1 80 90 2-s2.0-74549178528 10.1161/CIRCULATIONAHA.109.880187
99. Ehrentraut H., Weber C., Ehrentraut S., Schwederski M., Boehm O., Knuefermann P., Meyer R., Baumgarten G., The toll-like receptor 4-antagonist eritoran reduces murine cardiac hypertrophy. European Journal of Heart Failure 2011 13 6 602 610 2-s2.0-79957867141 10.1093/eurjhf/hfr035
100. Barber R. C., Maass D. L., White D. J., Chang L.-Y. E., Horton J. W., Molecular or pharmacologic inhibition of the CD14 signaling pathway protects against burn-related myocardial inflammation and dysfunction. Shock 2008 30 6 705 713 2-s2.0-58149269009 10.1097/SHK.0b013e31816f6caa
101. Piao W., Vogel S. N., Toshchakov V. Y., Inhibition of TLR4 signaling by TRAM-derived decoy peptides in vitro and in vivo. The Journal of Immunology 2013 190 5 2263 2272
102. Matsunaga N., Tsuchimori N., Matsumoto T., Ii M., TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Molecular Pharmacology 2011 79 1 34 41 2-s2.0-78651300299 10.1124/mol.110.068064
103. Chansrichavala P., Chantharaksri U., Sritara P., Chaiyaroj S. C., Atorvastatin attenuates TLR4-mediated NF- B activation in a MyD88-dependent pathway. Asian Pacific Journal of Allergy and Immunology 2009 27 1 49 57 2-s2.0-67749122584
104. Földes G., von Haehling S., Okonko D. O., Jankowska E. A., Poole-Wilson P. A., Anker S. D., Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. International Journal of Cardiology 2008 124 1 80 85 2-s2.0-38149017709 10.1016/j.ijcard.2006.12.024
105. Yang J., Jiang H., Yang J., Ding J.-W., Chen L.-H., Li S., Zhang X.-D., Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF- B signaling pathway. Molecular and Cellular Biochemistry 2009 330 1-2 39 46 2-s2.0-73349124780 10.1007/s11010-009-0098-1
106. Wen H. L., Liang Z. S., Zhang R., Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovascular Diabetology 2013 12 50
107. Westermann D., Van Linthout S., Dhayat S., Dhayat N., Escher F., Bücker-Gärtner C., Spillmann F., Noutsias M., Riad A., Schultheiss H.-P., Tschöpe C., Cardioprotective and anti-inflammatory effects of interleukin converting enzyme inhibition in experimental diabetic cardiomyopathy. Diabetes 2007 56 7 1834 1841 2-s2.0-34347405900 10.2337/db06-1662 (Pubitemid 47025453)
108. Fann D. Y., Lee S. Y., Manzanero S., Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death & Disease 2013 4, article e790
109. Larsen C. M., Faulenbach M., Vaag A., Vølund A., Ehses J. A., Seifert B., Mandrup-Poulsen T., Donath M. Y., Interleukin-1-receptor antagonist in type 2 diabetes mellitus. The New England Journal of Medicine 2007 356 15 1517 1526 2-s2.0-34247170807 10.1056/NEJMoa065213 (Pubitemid 46588416)
110. Geiler J., McDermott M. F., Gevokizumab, an anti-IL-1 β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Current Opinion in Molecular Therapeutics 2010 12 6 755 769 2-s2.0-79952969400
111. Stienstra R., Joosten L. A. B., Koenen T., Van Tits B., Van Diepen J. A., Van Den Berg S. A. A., Rensen P. C. N., Voshol P. J., Fantuzzi G., Hijmans A., Kersten S., Müller M., Van Den Berg W. B., Van Rooijen N., Wabitsch M., Kullberg B.-J., Van Der Meer J. W. M., Kanneganti T., Tack C. J., Netea M. G., The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metabolism 2010 12 6 593 605 2-s2.0-78649498271 10.1016/j.cmet.2010.11.011
112. Shaw R. J., Lamia K. A., Vasquez D., Koo S.-H., Bardeesy N., DePinho R. A., Montminy M., Cantley L. C., Medicine: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005 310 5754 1642 1646 2-s2.0-28844433635 10.1126/science.1120781 (Pubitemid 41780780)
113. Caton P. W., Nayuni N. K., Kieswich J., Khan N. Q., Yaqoob M. M., Corder R., Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. Journal of Endocrinology 2010 205 1 97 106 2-s2.0-77949493599 10.1677/JOE-09-0345
114. Zheng Z., Chen H., Li J., Li T., Zheng B., Zheng Y., Jin H., He Y., Gu Q., Xu N., Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin. Diabetes 2012 61 1 217 228 2-s2.0-84555188488 10.2337/db11-0416
115. Lamkanfi M., Mueller J. L., Vitari A. C., Misaghi S., Fedorova A., Deshayes K., Lee W. P., Hoffman H. M., Dixit V. M., Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. Journal of Cell Biology 2009 187 1 61 70 2-s2.0-70449727077 10.1083/jcb.200903124
116. Jourdan T., Godlewski G., Cinar R., Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nature Medicine 2013 19 9 1132 1140
117. Ares-Carrasco S., Picatoste B., Camafeita E., Carrasco-Navarro S., Zubiri I., Ortiz A., Egido J., López J. A., Tuñón J., Lorenzo O., Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPAR α in the associated hypertrophy. Journal of Proteomics 2012 75 6 1816 1829 2-s2.0-84857653408 10.1016/j.jprot.2011.12.023
118. Rosenson R. S., Wright R. S., Farkouh M., Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. American Heart Journal 2012 164 5 672 680
119. Dong X. C., Sirtuin biology and relevance to diabetes treatment. Diabetes Management 2012 2 3 243 257
120. Lee T. I., Kao Y. H., Chen Y. C., Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. Diabetes Research and Clinical Practice 2013 100 3 330 339
121. Xu J., Racke M. K., Drew P. D., Peroxisome proliferator-activated receptor- α agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. Journal of Neurochemistry 2007 103 5 1801 1810 2-s2.0-36249015459 10.1111/j.1471-4159.2007.04875.x (Pubitemid 350126611)
122. Ta N. N., Schuyler C. A., Li Y., Lopes-Virella M. F., Huang Y., DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. Journal of Cardiovascular Pharmacology 2011 58 2 157 166 2-s2.0-80051785333 10.1097/FJC.0b013e31821e5626
123. Daoudi M., Hennuyer N., Borland M. G., Touche V., Duhem C., Gross B., Caiazzo R., Kerrconte J., Pattou F., Peters J. M., Staels B., Lestavel S., PPAR β / δ activation induces enteroendocrine L cell GLP-1 production. Gastroenterology 2011 140 5 1564 1574 2-s2.0-79955435707 10.1053/j.gastro.2011. 01.045
124. Milne J. C., Lambert P. D., Schenk S., Carney D. P., Smith J. J., Gagne D. J., Jin L., Boss O., Perni R. B., Vu C. B., Bemis J. E., Xie R., Disch J. S., Ng P. Y., Nunes J. J., Lynch A. V., Yang H., Galonek H., Israelian K., Choy W., Iffland A., Lavu S., Medvedik O., Sinclair D. A., Olefsky J. M., Jirousek M. R., Elliott P. J., Westphal C. H., Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007 450 7170 712 716 2-s2.0-36749087548 10.1038/nature06261 (Pubitemid 350207685)